SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Chung-Cheng Wang, Chun-Hou Liao, Hann-Chorng Kuo, Clinical guidelines for male lower urinary tract symptoms associated with non-neurogenic overactive bladder, Urological Science, 2015,

    CrossRef

  2. 2
    Forrest C. Jellison, Evaluation and Treatment of Overactive Bladder after History of Cancer Treatment, Current Bladder Dysfunction Reports, 2015, 10, 1, 31

    CrossRef

  3. 3
    Karen Noblett, Steven Siegel, Jeffrey Mangel, Tomas L. Griebling, Suzette E. Sutherland, Erin T. Bird, Craig Comiter, Daniel Culkin, Jason Bennett, Samuel Zylstra, Fangyu Kan, Kellie Chase Berg, Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder, Neurourology and Urodynamics, 2015, 34, 2
  4. 4
    Hann-Chorng Kuo, Treatment of overactive bladder: Past, present, and future, Urological Science, 2015,

    CrossRef

  5. 5
    Hann-Chorng Kuo, Botulinum Toxin A Injections for Non-neurogenic Overactive Bladder, Current Bladder Dysfunction Reports, 2014, 9, 3, 254

    CrossRef

  6. 6
    Axel Hegele, Sonja Knippschild, Carsten Frohme, Jörg Hänze, Peter Olbert, Rainer Hofmann, Changes in prostaglandin E2 in patients with idiopathic overactive bladder syndrome after botulinum toxin type A treatment: is there a clinical benefit?, BMC Urology, 2014, 14, 1, 85

    CrossRef

  7. 7
    Mang L. Chen, Christopher J. Chermansky, Bing Shen, James R. Roppolo, William C. de Groat, Changfeng Tai, Electrical Stimulation of Somatic Afferent Nerves in the Foot Increases Bladder Capacity in Healthy Human Subjects, The Journal of Urology, 2014, 191, 4, 1009

    CrossRef

  8. 8
    Katherine Warren, Helena Burden, Paul Abrams, Lower urinary tract symptom, Current Opinion in Urology, 2014, 24, 1, 3

    CrossRef

  9. 9
    Altaf Mangera, Christopher R Chapple, OnabotulinumtoxinA for the treatment of overactive bladder, Clinical Investigation, 2014, 4, 3, 281

    CrossRef

  10. 10
    Lanka Abeywickrama, Angamuthu Arunkalaivanan, Monica Quinlan, Repeated botulinum toxin type A (Dysport®) injections for women with intractable detrusor overactivity: a prospective outcome study, International Urogynecology Journal, 2014, 25, 5, 601

    CrossRef

  11. 11
    Maria Paola Bertapelle, Mario Vottero, Giulio Del Popolo, Marco Mencarini, Edoardo Ostardo, Michele Spinelli, Antonella Giannantoni, Anna D’Ausilio, Sacral neuromodulation and Botulinum toxin A for refractory idiopathic overactive bladder: a cost-utility analysis in the perspective of Italian Healthcare System, World Journal of Urology, 2014,

    CrossRef

  12. 12
    Pravisha Ravindra, Benjamin L. Jackson, Richard J. Parkinson, Botulinum toxin type A for the treatment of non-neurogenic overactive bladder: does using onabotulinumtoxinA (Botox®) or abobotulinumtoxinA (Dysport®) make a difference?, BJU International, 2013, 112, 1
  13. 13
    J. Seth, M. S. Khan, P. Dasgupta, A. Sahai, Botulinum Toxin—What Urologic Uses Does the Data Support?, Current Urology Reports, 2013, 14, 3, 227

    CrossRef

  14. 14
    R. Caremel, J.-N. Cornu, J. Kerdraon, E. Castel-Lacanal, C. Bastide, F. Bruyere, L. Guy, G. Karsenty, Les médicaments de la vessie, Progrès en Urologie, 2013, 23, 15, 1271

    CrossRef

  15. 15
    J. Quentin Clemens, Long-term outcome of the use of intravesical botulinum toxin for the treatment of overactive bladder (OAB), Yearbook of Urology, 2013, 2013, 50

    CrossRef

  16. 16
    Tina G. Rashid, Jeremy L. Ockrim, Male incontinence, Current Opinion in Urology, 2013, 23, 6, 545

    CrossRef

  17. 17
    Sheng-Fu Chen, Hann-Chorng Kuo, Therapeutic outcome and patient adherence to repeated onabotulinumtoxinA detrusor injections in chronic spinal cord-injured patients and neurogenic detrusor overactivity, Journal of the Formosan Medical Association, 2013,

    CrossRef

  18. 18
    Jamie M. Bartley, Emily S. Blum, Larry T. Sirls, Kenneth M. Peters, Understanding Clinic Options for Overactive Bladder, Current Urology Reports, 2013, 14, 6, 541

    CrossRef

  19. 19
    S. Gaillet, P. Bardot, B. Bernuz, R. Boissier, K. Lenne-Aurier, I. Thiry-Escudier, H. Tournebise, E. Lechevallier, G. Karsenty, Five years follow-up study and failures analysis of Botulinum toxin repeated injections to treat neurogenic detrusor overactivity, Progrès en Urologie, 2012, 22, 17, 1064

    CrossRef

  20. 20
    Antonio Marte, Onabotulinumtoxin A for Treating Overactive/Poor Compliant Bladders in Children and Adolescents with Neurogenic Bladder Secondary to Myelomeningocele, Toxins, 2012, 5, 1, 16

    CrossRef